Trials / Completed
CompletedNCT00893217
BEYOND Pilot Study
Double-blind, Randomized, Parallel Group, Multicenter Study of the Safety and Tolerability of Betaseron 500 Mcg Subcutaneously Every Other Day and Betaseron 250 Mcg Subcutaneously Every Other Day for at Least 12 Weeks in Patients With RRMS
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to valuate safety and tolerability of Betaseron.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Betaseron (Interferon beta-1b, BAY86-5046) | 250 mcg |
| DRUG | Betaseron (Interferon beta-1b, BAY86-5046) | 500 mcg |
Timeline
- Start date
- 2002-11-01
- Completion
- 2003-06-01
- First posted
- 2009-05-05
- Last updated
- 2009-11-09
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00893217. Inclusion in this directory is not an endorsement.